Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Applied DNA Sciences Restructures Operations to Focus on Synthetic DNA Manufacturing for Gene Therapies
Applied DNA Sciences implemented a 27% workforce reduction and ceased operations at Applied DNA Clinical Labs to focus exclusively on its synthetic DNA manufacturing subsidiary LineaRx.
Laverock Therapeutics Raises £20M in Expanded Seed Funding, Reports Positive Data for Cancer Cell Therapy Programs
Laverock Therapeutics has expanded its seed funding round to more than £20 million, with the latest £6.5 million extension led by Calculus Capital and including participation from Eli Lilly and Company.
CDC's Reconstituted Vaccine Advisory Panel Votes to Eliminate Thimerosal from All Flu Vaccines
The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.
Cambridge Healthcare Innovations Unveils Quattrii Inhaler Technology to Deliver Large-Dose Biologics and mRNA Therapies
Cambridge Healthcare Innovations has announced Quattrii, a dry powder inhaler engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation with at least 70% lung delivery efficiency.
Fareva Opens New GMP Sterile Pilot Unit in France to Support Biotech Drug Manufacturing
Fareva has launched a new GMP sterile pilot unit at its Pau site in France, designed to produce liquid and lyophilized injectable forms for biotechnology-derived medicines.
COVID-19 Vaccination Reduces Severe Kidney Damage Risk in Hospitalized Patients, UCLA Study Finds
UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.
Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025
A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.
Moderna Seeks External Partners to Fund Late-Stage Vaccine Trials for Latent Virus Programs
Moderna is actively seeking partnerships with pharmaceutical companies and financial firms to fund late-stage trials for its latent virus vaccine portfolio, including programs targeting Epstein-Barr virus, herpes simplex virus, and varicella-zoster virus.
National Resilience Winds Down Six Manufacturing Facilities Despite $2.25 Billion in Total Funding
National Resilience announced plans to wind down six manufacturing facilities across California, Massachusetts, and Florida, citing that capacity expansion has outpaced industry demand.
FDA Approves Moderna's Next-Generation COVID-19 Vaccine mRNA-1283 with Enhanced Efficacy
The FDA has approved Moderna's new COVID-19 vaccine mRNA-1283 (mNEXSPIKE), marking the first authorization under updated federal guidelines prioritizing vaccination for adults 65 and older.